Full Breakdown
U.S. Department of Justice Reclassifies Marijuana as Less Dangerous
4/24/2026, 12:21:50 AM
Major Policy Shift in Drug Classification
On April 23, 2026, the U.S. Department of Justice, under Acting Attorney General Todd Blanche, announced a significant reclassification of marijuana, moving it from Schedule I to Schedule III under the Controlled Substances Act. This change recognizes state-licensed and FDA-approved marijuana products as having accepted medical uses and a lower potential for abuse, aligning federal policy more closely with the evolving state-level legalization landscape. The reclassification does not legalize marijuana federally but alters its regulatory framework, potentially reshaping the $47 billion cannabis industry.
Implications for the Cannabis Industry
The reclassification is expected to lower barriers for research, ease tax burdens, and facilitate funding for cannabis companies. Notable firms such as Canopy Growth, Tilray Brands, and Trulieve Cannabis saw their stock prices increase by 6% to 13% following the announcement. Blanche emphasized that this action would enhance patient care and provide doctors with more reliable information regarding cannabis use. The move follows a December 2025 executive order from President Donald Trump, which directed the Justice Department to expedite the reclassification process.
Background and Context
Historically, marijuana has been classified alongside highly addictive substances like heroin and LSD, a designation that has faced criticism for being outdated. Currently, 40 states have legalized marijuana for medical use, and 24 states, along with the District of Columbia, have legalized it for recreational use. Only Idaho and Kansas maintain outright bans on marijuana. The Biden administration had previously initiated a similar reclassification process in 2024, but it was not finalized before Trump returned to office.
Official Statements & Responses
Blanche stated, “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information.” Irwin Simon, CEO of Tilray, remarked, “Today marks a pivotal moment for the United States... federal policy is finally aligning with science, medicine, and most importantly, patient needs.” However, critics like Kevin Sabet, CEO of Smart Approaches to Marijuana, labeled the order as “a tax break to Big Weed,” arguing it sends a confusing message about marijuana's risks.
Criticism & Opposition
Opposition to the reclassification exists, particularly among some Republican senators who have urged the administration to maintain strict marijuana regulations. Critics express concern that the reclassification may inadvertently promote marijuana use among youth and downplay its potential harms. Sabet criticized the decision, stating, “With this move, we are now confronted with the most pro-drug administration in our history.”
What's Next
The Department of Justice plans to initiate an expedited hearing on June 29, 2026, to gather evidence and expert opinions on the broader reclassification of marijuana. This process may further influence how marijuana is regulated and researched in the United States, potentially leading to more comprehensive changes in federal drug policy.
Conflicting Reports & Gaps
While the reclassification is a significant step, it does not legalize marijuana at the federal level, and criminal penalties for illegal use remain in place. The implications of this reclassification on state-level operations, particularly in states where recreational marijuana is also sold, remain unclear. Additionally, the ongoing debate about marijuana's safety and efficacy continues, with varying opinions on its impact on public health.
